Key result
Among 1,744 patients with lung cancer, the incidence of venous thromboembolism was 3.4%, and VTE was associated with significantly longer overall survival in stage IIIB-IV patients (p=0.041).
Why the study?
Venous thromboembolism is a frequent complication of cancer-associated thrombosis critical to cancer treatment and prognosis, prompting this investigation of its incidence and risk factors in lung cancer.
Observational (n=1,744)
Yes
In a Japanese registry of lung cancer patients, the incidence of VTE was 3.4%, and appropriate diagnosis and treatment of VTE may allow for continued cancer therapy without compromising survival.
VTE linked to longer survival in advanced lung cancer; leaves open whether detection or treatment improves outcomes.
BACKGROUND: Venous thromboembolism (VTE) is a frequent complication of cancer-associated thrombosis, and its management is critical when considering cancer treatment selection and prognosis. The aim of this study was to investigate the incidence and risk factors for VTE in patients with lung cancer using the CS-Lung003 platform, a multicenter prospective observational study of advanced lung cancer. METHODS: Patients with a pathologic diagnosis of lung cancer at any stage were included. The incidence of VTE was calculated using the CS-Lung003 database, and risk factors were examined using logistic regression analysis. RESULTS: The analysis included 1744 patients (80 % male). Sixty patients (3.4 %) had VTE at/after enrollment in the CS-Lung003 trial. The median age was 69 years (range 63-76) in the group without VTE and 72 years (range 67-77) in the group with VTE. Adenocarcinoma was diagnosed in 58.7 % of patients in the group without VTE and 46.7 % in the group with VTE. Univariate analysis revealed male sex, body weight, and hypertension as risk factors for VTE. Overall survival was 29.1 months in the group without VTE and 30.6 months in the group with VTE. Among patients with stage IIIB-IV, the VTE group showed significantly longer overall survival compared with the non-VTE group (p = 0.041). CONCLUSIONS: The incidence of VTE in this study was low, suggesting that there may have been patients with VTE complications that were not reported in the registry. In addition, most patients with VTE received therapeutic intervention; appropriate diagnosis and treatment may have allowed cancer treatment to continue. Appropriate diagnosis and treatment of VTE might allow lung cancer therapy continuation without compromising survival. CLINICAL TRIAL REGISTRY/REGISTRATION NUMBER: UMIN-CTR/UMIN000026696.
No takes yet. Share an insight, caveat, or question.
Tsubata et al. (2025) conducted an observational in Lung cancer (n=1,744). Lung cancer was evaluated on Incidence of venous thromboembolism (VTE). Among 1,744 patients with lung cancer, the incidence of venous thromboembolism was 3.4%, and VTE was associated with significantly longer overall survival in stage IIIB-IV patients (p=0.041).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: